Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) saw a large decrease in short interest in May. As of May 29th, there was short interest totaling 12,411 shares, a decrease of 98.9% from the May 14th total of 1,080,288 shares. Based on an average trading volume of 4,135 shares, the short-interest ratio is presently 3.0 days.

Innovent Biologics Stock Up 5.5%

OTCMKTS IVBXF traded up $0.50 during trading hours on Thursday, hitting $9.60. 333 shares of the company’s stock traded hands, compared to its average volume of 5,214. Innovent Biologics has a 52-week low of $9.10 and a 52-week high of $15.12. The firm’s 50-day moving average is $10.65 and its 200-day moving average is $10.76.

About Innovent Biologics

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).